Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chemogenomics: Serendipity on a Large Scale

This article was originally published in Start Up

Executive Summary

To eliminate a bottle neck in target validation, pharmaceutical firms are turning to a new model known as chemogenomics, the use of small molecule drugs as probes to tease out a phenotypic response from multiple poorly-understood targets. One of the most ambitious efforts to date, Amphora Discovery Corp., a spin-out of lab-on-a-chip firm Caliper Technologies, was founded in September to build a database detailing the interactions of as many as 4000-12000 biological targets with half a million compounds.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts